Scientific discovery dossier · Experimental discoveries
STIM1/STIM2 — CD8+ T-cell antitumor immunity
STIM1 and STIM2-mediated Ca2+ influx regulates antitumour immunity by CD8+ T cells
- Record type
- Preclinical scientific discovery (not a clinical trial)
- Publication
- Peer-reviewed
- DOI
- 10.1002/emmm.201302989
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
- Scope / models
- Multiple / solid tumors — Fare modelleri; CD8+ T hücre Ca²⁺ girişi
- Molecular mechanism
- STIM1/STIM2-mediated Ca²⁺ influx regulates CD8+ effector function; linked to tumor immune surveillance.
- Experimental models
- Conditional knockout mice; in vivo tumor-immunity experiments.
- Translational distance
- Generates immunotherapy-combination hypotheses; no clinical SOCE-inhibitor indication.
- Research biomarker
- STIM1 / STIM2 (SOCE)
For patients
What is being studied? Mouse studies suggest calcium signaling may matter for immune cells fighting cancer. This is not a pharmacy drug.
Why promising? Showed Ca²⁺ entry may be required for T-cell antitumor efficacy, providing conceptual ground for IO translation.
What is not proven? Human clinical benefit; safe pharmacologic SOCE modulation; use in surgical oncology practice.
Is this standard care today? No — this is a laboratory/scientific discovery dossier, not a treatment option.
For clinicians
DOI 10.1002/emmm.201302989. Basic immunology; no clinical claim.
Limitations: Preklinik; farmakolojik SOCE inhibisyonunun toksisite riski (immün baskılanma) ayrı değerlendirilmeli.